Implementing preoperative Botulinum toxin A and progressive pneumoperitoneum through the use of an algorithm in giant ventral hernia repair by Yurtkap, Y. et al.
Vol.:(0123456789) 
Hernia (2021) 25:389–398 
https://doi.org/10.1007/s10029-020-02226-2
ORIGINAL ARTICLE
Implementing preoperative Botulinum toxin A and progressive 
pneumoperitoneum through the use of an algorithm in giant ventral 
hernia repair
Y. Yurtkap1 · M. M. J. van Rooijen1 · S. Roels2 · J. M. L. Bosmans2 · O. Uyttebroek3 · J. F. Lange1,4 · F. Berrevoet3,5 
Received: 25 February 2020 / Accepted: 19 April 2020 / Published online: 3 June 2020 
© Springer-Verlag France SAS, part of Springer Nature 2020
Abstract
Background Repair of large ventral hernias with loss of domain can be facilitated by preoperative Botulinum toxin A (BTA) 
injections and preoperative progressive pneumoperitoneum (PPP). The aim of this study is to evaluate the outcomes of ven-
tral hernioplasty using a standardized algorithm, including component separation techniques, preoperative BTA and PPP.
Methods All patients between June 2014 and August 2018 with giant hernias (either primary or incisional) of more than 
12 cm width were treated according to a previously developed standardized algorithm. Retrospective data analysis from a 
prospectively collected dataset was performed. The primary outcome was closure of the anterior fascia. Secondary outcomes 
included complications related to the preoperative treatment, postoperative complications, and recurrences.
Results Twenty-three patients were included. Median age was 65 years (range 28–77) and median BMI was 31.4 (range 
22.7–38.0 kg/m2). The median loss of domain was 29% (range 12–226%). For the primary and secondary endpoints, 22 
patients were analyzed. Primary closure of the anterior fascia was possible in 82% of all patients. After a median follow-up 
of 19.5 months (range 10–60 months), 3 patients (14%) developed a hernia recurrence and 16 patients (73%) developed 23 
surgical site occurrences, most of which were surgical site infections (54.5%).
Conclusion Our algorithm using both anterior or posterior component separation, together with preoperative BTA injections 
and PPP, achieved an acceptable fascial closure rate. Further studies are needed to explore the individual potential of BTA 
injections and PPP, and to research whether these methods can prevent the need for component separation, as postoperative 
wound morbidity remains high in our study.
Keywords Ventral hernia · Loss of domain · Component separation techniques · Botulinum A · Progressive 
pneumoperitoneum
Introduction
One of the most prevalent complications after midline 
laparotomy is an incisional hernia [1]. Incisional hernias 
often require surgical repair as they may cause discomfort 
and pain [2]. Giant hernias, which are more than 10 cm 
in width, or hernias with loss of domain (LOD) of more 
than 20%, in which the abdominal cavity is unable to fully 
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accommodate the abdominal contents within its fascial 
boundaries, pose additional difficulties [3, 4]. In these her-
nias, closure of the fascia is impossible or will cause high 
pressure with a substantial risk of complications, such as 
abdominal compartment syndrome and pulmonary dys-
function [4]. Despite the risk of complications, surgical 
closure of a hernia with LOD might be indicated when 
quality of life is low. LOD can cause long-term disabil-
ity, loss of core muscles, back pain, paradoxical respira-
tory motion, mesenteric edema, poor bowel function, skin 
necrosis, enterocutaneous fistula, and cosmetic issues [4]. 
For the repair of a giant hernia (with or without loss of 
domain), additional medialization of the rectus abdominis 
muscles might be required to achieve tension-free closure. 
Anterior or posterior component separation techniques 
(i.e. (modified) Ramirez [5] or transverse abdominis 
release (TAR)) can be used to obtain additional mediali-
zation of the rectus abdominis muscles [6]. In addition to 
component separation techniques, a progressive preopera-
tive pneumoperitoneum (PPP) has shown to be a safe way 
to facilitate closure in hernias with LOD [7–10]. The use 
of PPP was first described by Goñi Moreno in 1947 [11]. 
PPP causes gradual expansion of the abdominal muscles 
and pneumatic lysis of adhesions in the abdominal cavity 
or hernia sac.
A more recent finding is that Botulinum toxin A (BTA) 
can be used to facilitate closure too, as it lowers the tension 
on the lateral abdominal muscles [12–14]. The combina-
tion of BTA and PPP, however, has been little described; 
the few studies that have been done suggest positive results 
[15]. This combination, however, is not always necessary 
for adequate repair. Additionally, PPP is rather expensive 
because it might require preoperative hospital stay [16].
A standardized preoperative strategy is required for 
patients with a giant hernia, as preoperative BTA and/or PPP 
can aid fascial closure, but their effects cannot be adjusted 
intra-operatively.
This preoperative strategy would ideally distinguish 
between patients with a giant hernia that [1] could be treated 
without preoperative aids, [2] patients in whom BTA alone 
would suffice, and [3] patients that would need the combina-
tion of BTA and PPP. As current literature is void of recom-
mendations for use of these preoperative aides, an empirical 
algorithm was developed based on clinical experience. This 
retrospective analysis aimed to determine the closure rate of 
the anterior fascia aided by Botulinum toxin A and/or pre-
operative progressive pneumoperitoneum by the use of the 
algorithm, and could also serve as an evaluation of whether 
the algorithm is valuable in determining the need for these 
preoperative tools in specific patient groups. Secondary out-
comes included complications related to the preoperative 
treatment, postoperative complications, and recurrences.
Methods
First, a preoperative strategy or algorithm for the treatment 
of complicated giant ventral hernias was developed in a large 
tertiary care university hospital in Ghent, Belgium. The 
algorithm was based on both hernia width and the presence 
or absence of loss of domain (Fig. 1). The rationale behind 
the algorithm was based on the primary goal of achieving 
Fig. 1  Treatment algorithm
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anterior fascial closure after hernia repair. With this in mind, 
the interventions used in sequential fashion were (1) the gold 
standard retromuscular repair (Rives–Stoppa [17, 18]); (2) 
anterior component separation technique; (3) BTA injec-
tions; and (4) PPP. In hernias with a width of up to 10 cm, 
retromuscular repair was performed. The size of the defect at 
which the additional tool of anterior CST was added was set 
as 14 cm. BTA can be considered when the surgeon believes 
anterior fascia closure might still not be achievable despite 
the use of anterior CST, and from 18 cm hernia width, PPP 
can be considered to implement some “reserve” to prevent 
the surgeon from being unable to close the fascia intraopera-
tively. In large hernias over 22 cm of width, volume reduc-
tion and maximal medial advancement of the rectus muscles 
are desired; all tools are hypothesized to be needed in this 
specific complicated subset of patients.
Approval of the Medical Ethics Committee was obtained 
prior to this study. Adult patients with an elective repair 
of a giant hernia, either primary or incisional, who pre-
sented between June 2014 and August 2018 were treated 
accordingly.
As illustrated in Fig. 1, BTA injections (Botulinum toxin 
A, Allergan, Inc., Irvine, California) and PPP were adminis-
tered to patients with a clinically estimated hernia width of 
more than 18 cm, thickened oblique muscles based on com-
puted tomography (CT) examinations and/or a LOD ≥ 20% 
based on volumetric measures on CT [19]. BTA injections 
were administered according to the protocol written by Ziel-
inksi et al. [20]. BTA injections of 300 units dissolved in 
150 cc 0.9% sodium chloride solution were given at three 
levels bilaterally. The injections were performed under 
ultrasound guidance by an experienced radiologist, using a 
Philips iU22 device equipped with a 3–9 MHz linear trans-
ducer and a biopsy guide. The injections were given into the 
transverse abdominal muscle, internal oblique, and external 
oblique muscle.
For PPP, after cardiopulmonary evaluation, a catheter 
(Medionics’ Swan Neck Coil 2 cuff peritoneal dialysis, inner 
diameter of 2.6 mm and outer diameter of 5 mm) was placed 
through open surgery, under general anesthesia, subcos-
tally in the right or left hypochondriac region at the day of 
admission. Up to 2 L of ambient air were insufflated into the 
abdominal cavity at day zero. On daily basis and until her-
nia repair, a variable amount of ambient air was insufflated 
into the abdominal cavity through a microporous filter, up 
until the point where the patient was no longer comfortable. 
All patients were hospitalized during insufflation. Throm-
boprophylaxis (low molecular weight heparin, LMWH) at 
therapeutic dose was administered daily.
Mesh was used for all hernia repairs, which was fixated 
with continuous suture of Prolene 2-0.
Anterior fascial closure after hernia repair surgery took 
place with a running long-term absorbable polydioxanone 
suture 0, in a small step fashion with a small bite configura-
tion. Suture length to wound length ratio was not measured.
Data collection
Retrospective data extraction from this prospectively 
collected data was performed. The following data were 
extracted from medical records: achievement of primary 
anterior fascial closure, baseline characteristics (age, gen-
der, body mass index (BMI), smoking, medical history, and 
previous hernia surgery), hernia characteristics based on 
the EHS classification [21], data on the surgical procedure 
(ASA classification, surgery duration, type of repair, anti-
biotic prophylaxis, type and location of mesh), and follow-
up time. Postoperative data in the form of postoperative 
complications, the surgical site occurrences (SSO), hernia 
recurrences, and reoperations were collected. A surgical site 
occurrence was defined as a surgical site infection (super-
ficial, deep, mesh infection), seroma, hematoma, wound 
and fascia dehiscence, or enterocutaneous fistula forma-
tion. Information about BTA and PPP (side of the catheter 
(right or left), number of days for insufflation, amount of 
insufflated air) was collected. Additionally, the size of the 
hernia defect and volume of the hernia sac were measured 
from CT examinations before and after BTA and/or PPP, 
when available. The pre- and post-BTA abdominal muscle 
length was measured at the level of the mid-third lumbar 
vertebra and the inside of the abdominal wall. Measurements 
started at the paravertebral muscles and ended in the midline 
(or hernia) using post-processing analyses with SyngoVia 
Version VB20A (Siemens). All data were analyzed using 
SPSS ® Statistics for Windows, version 24.0.0.1, IBM corp. 
Armonk, NY.
Results
A total of 23 patients (12 males and 11 females), with a 
median age of 65 years (range 28–77 years) were treated 
between June 2014 and August 2018. Median BMI was 
31.4 kg/m2 (range 22.7–43.3 kg/m2). Three patients (13%) 
were current smokers, 10 (43.5%) were ex-smokers, and 
10 (43.5%) were non-smokers. Seven patients (30.4%) had 
diabetes mellitus. All patient characteristics are listed in 
Table 1.
Hernia characteristics
Fourteen patients (60.9%) had a recurrent hernia and nine 
patients (39.1%) had a primary hernia. CT scans to evaluate 
preoperative loss of domain were available for 17 patients 
(73.9%). The median LOD was 29% (range 12–226%), based 
on hernia sac volume to abdominal cavity volume ratio.
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BTA and PPP
Twenty patients (87%) received BTA injections with a 
median of 45 days before surgery (range 28–119 days). The 
median difference in muscle length on the right side pre- and 
post-BTA injections was 3.6 cm (cm) (range 0.4–7.6 cm) 
and on the left side 2.7 cm (0.7–7.9 cm). Seventeen patients 
(73.9%) underwent PPP. A median of 10.2 L of air, with a 
range of 6.4–19.1 L, was insufflated over a median period of 
12 days (range 7–21 days). The insufflation of the abdominal 
cavity was initiated 14 days before surgery (median, range 
5–43). The hernia sac volume (HSV) to abdominal cav-
ity volume (ACV) ratio was 0.29 before BTA and/or PPP 
(median, range 0.12–2.26, 6 CT scans missing) and 0.33 
after BTA and/or PPP (range 0.09–2.00, 6 CT scans miss-
ing). Fourteen patients (60.9%) received the combination of 
BTA injections and PPP. Data regarding patients having both 
BTA and PPP are summarized in Table 2. Several patients 
did not require both BTA and PPP based on their clinical 
presentation and our algorithm. For example, in case LOD 
was present without thickened lateral abdominal wall mus-
culature, only PPP was administered preoperatively. When 
we evaluate the practical usefulness of our algorithm, in the 
hernia group with widths between 14 and 18 cm, the actu-
ally performed pre- and intra-operative treatment differed in 
seven out of nine patients (77.8%) from what was suggested 
according to the algorithm. In contrast, in all patients from 
both groups with hernias over 18 cm, the proposed surgical 
technique from the algorithm was used. Only three out of 
14 patients in those two groups (21.4%) received different 
preoperative management than suggested by the algorithm. 
Details on the pre- and intraoperative operative treatment 
per treatment group from the algorithm are summarized in 
Table 3. Additionally, the hernia characteristics using the 
EHS classification are presented in Table 3 [21]. 
Complications of PPP and BTA
The administration of BTA injections did not result 
in complications. The use of PPP, however, resulted in 
complications in five patients. One patient had a cardiac 
arrest at day 5 of PPP and cardiopulmonary resuscitation 
was performed successfully. Post hoc evaluation showed 
an AV block grade II, with no signs of pulmonary or air 
embolisms. A PPP catheter was replaced approximately 
2 weeks after the cardiac arrest. Consequently, the patient 
developed a liver hematoma, which was drained surgically. 
Another patient had a hematoma retro rectus at the site of 
the catheter during PPP, confirmed with a CT scan, which 
Table 1  Patient characteristics
BMI body mass index, ASA American Society of Anesthesiologists
Patient characteristics Overall
N = 23
Age, years, median (range) 65 (28–77)
Male (%) 12 (52.2)
BMI, kg/m2 (range) 31.4 (22.7–43.3)




Diabetes mellitus (%) 7 (30.4)
Hypertension (%) 16 (69.6)
Cardiac disease (%) 9 (39.1)
Pulmonary disease (%) 8 (34.8)
Hepatic disease (%) 3 (13.0)
Renal disease (%) 0 (0)
History of malignant disease (%) 8 (34.8)
Corticosteroids use (%) 1 (4.3)
Primary hernia (%) 9 (39.1)
Recurrent hernia (%) 14 (60.9)




Table 2  BTA and preoperative progressive pneumoperitoneum
All values are median (range) or n (%)
PPP preoperative progressive pneumoperitoneum, HSV hernia sac 
volume, ACV abdominal cavity volume, ∆ difference in muscle length
Treatment Overall
N = 23
BTA, number (%) 20 (87.0)
 Days before surgery 45 (8–120)
 ∆ muscle length pre- and post-BTA, right (cm) 3.6 (0.4–7.6)
 ∆ muscle length pre- and post-BTA, left (cm) 2.7 (0.7–7.9)
PPP, number (%) 17 (73.9)
 Side drain, right (%) 16 (94.1)
 Total air (liters) 10.2 (6.4–19.1)
 Total days of air insufflation 12 (7–21)
 Days before surgery 14 (5–43)
 HSV/ACV ratio before BTA and/or PPP 0.31 (0.12–2.26)
 HSV/ACV ratio after BTA and/or PPP 0.33 (0.08–2.00)
BTA + PPP combination, number (%) 14 (60.7%)
 Days before surgery, BTA 43 (8–120)
 ∆ muscle length pre- and post-BTA, right (cm) 4.3 (0.4–7.6)
 ∆ muscle length pre- and post-BTA, left (cm) 4.2 (1.3–7.9)
 Days before surgery, PPP 14 (5–37)
 Side drain, right (%) 13 (92.9)
 Total air (L) 10.4 (6.4–19.1)
 Total days of air insufflation 11 (7–21)
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was drained during hernia repair. One patient was admit-
ted to the intensive care unit due to hemorrhagic shock 
based on an extensive hematoma after placement of the 
PPP catheter at day 5. This hematoma was drained surgi-
cally. One patient developed an enterocutaneous fistula 
during PPP. The fifth patient died preoperatively due to 
hemorrhage at the site of the bursa omentalis and multi-
organ failure after 5 days of PPP, and was, therefore, not 
evaluated in further analyses (Fig. 2).
Surgical characteristics
All abdominal hernia repairs (N = 22) were elective lapa-
rotomies. Hernia repair was performed by either anterior 
component separation or transversus abdominis release, 
except in one patient. This patient did not need compo-
nent separation and could be repaired without this tech-
nique. Intra-operatively, the median length of the hernia 
was 20 cm (range 8–30 cm) and the median width was 
21 cm (range 12–30 cm). Mesh localization was either 
Table 3  Surgical characteristics 
per subgroup from the 
algorithm
BMI body mass index, EHS European Hernia Society, BTA botulinum Toxin A, PPP progressive preopera-
tive pneumoperitoneum, CS component separation, TAR transverse abdominal release, Comb. combination










Bilateral anterior CS 
+BTA
+PPP
Age, years, median (range) 67 (46–74) 68 (63–77) 63 (28–69)
BMI, kg/m2 (range) 31.4 (24.7–43.0) 29.8 (22.7–36.8) 36.3 (25.5–43.3)
Recurrent hernia (%) 5 (55.6) 3 (50.0) 6 (75.0)
EHS classification
 M1-M4W3 1 (11.1) 2 (33.3) 2 (25.0)
 M1-M5W3 0 (0) 2 (33.3) 1 (12.5)
 M2-M4L2W3 1 (11.1) 0 (0) 0 (0)
 M2-M5W3 0 (0) 1 (16.7) 4 (50.0)
 M2-M5W2 1 (11.1) 0 (0) 0 (0)
 M2-M5L2W3 0 (0) 0 (0) 1 (12.5)
 M3-M4W3 1 (11.1) 0 (0) 0 (0)
 M3-M5W3 4 (44.4) 0 (0) 0 (0)
 L2-W3 1 (11.1) 0 (0) 0 (0)
 Missing 0 (0) 1 (16.7) 0 (0)
BTA only (%) 3 (33.3) 2 (33.3) 1 (12.5)
PPP only (%) 1 (11.1) 0 (0) 2 (25.0)
PPP + BTA (%) 5 (55.6) 4 (66.7) 5 (62.5)
Surgery (%) 9 (100.0) 5 (83.3) 8 (100.0)
Surgery time, minutes (range) 265 (150–399) 260 (220–370) 323 (215–396)
Type of surgery
 Anterior CS, bilateral (%) 2 (22.2) 5 (83.3) 8 (100.0)
 TAR, bilateral (%) 1 (11.1) 0 (0) 0 (0)
 Anterior CS, unilateral (%) 1 (11.1) 0 (0) 0 (0)
 TAR, unilateral (%) 1 (11.1) 0 (0) 0 (0)
 Comb. anterior CS and TAR 
(contralateral sides) (%)
3 (33.3) 0 (0) 0 (0)
 No CS (%) 1 (11.1) 0 (0) 0 (0)
 No repair (%) 0 (0) 1 (16.7) 0 (0)
Mesh location
 Intraperitoneal 4 (44.4) 5 (83.3) 8 (100.0)
 Retromuscular 5 (55.6) 0 (0) 0 (0)
Mesh type
 Synthetic 9 (100) 5 (83.3) 7 (87.5)
 Biologic 0 (0) 0 (0) 1 (12.5)
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intraperitoneal (N = 17, 77.3%) or retromuscular (N = 5, 
22.7%). Median length of the meshes used was 42 cm 
(range 28–50 cm) and median width was 32 cm (range 
26–38 cm). Median mesh surface (length × width) was 
1344  cm2 (range 572–1850  cm2). All patients were clini-
cally re-evaluated in July 2019. The follow-up period, 
therefore, ranged from 10 to 60 months, with a median 
follow-up of 19.5 months. All surgical characteristics can 
be found in Table 3.
Intra‑ and postoperative complications
With regard to the primary outcome, in four patients 
(18.1%), the anterior fascia could not be closed during the 
initial operation. One patient had a small bowel perfora-
tion during adhesiolysis, which was repaired immediately 
during the first operation, but a second stage repair a few 
days later was required. In three other patients (13.6%) the 
anterior layer could only be closed using a small part of the 
hernia sac to cover the intraperitoneal mesh. With regard 
to the secondary endpoints, 16 patients (72.7%) developed 
23 surgical site occurrences (SSOs) postoperatively (sum-
marized in Table 4). Twelve patients (54.5%) had a surgi-
cal site infection (SSI), of which six patients (26.1%) had a 
deep infection. One deep infection was managed by antibi-
otic treatment alone, two deep infections required (partly) 
surgical mesh removal, and the remaining three were treated 
with negative pressure therapy. Other SSOs included sero-
mas (N = 4, 18.2%), hematomas (N = 4, 18.2%), postopera-
tive fascia dehiscence (N = 3, 13.6%). None of these SSOs 
required additional therapy, except for one seroma, which 
was drained by ultrasound guidance and subsequently 
drained during surgery. No postoperative enterocutaneous 
fistulas were seen. Other complications included pneumo-
nias in three patients, of whom two needed admission to the 
intensive care unit. A total of three patients (13.6%) expe-
rienced a hernia recurrence, of which one received surgical 
repair. Hernia recurrence repair was performed and a syn-
thetic mesh was placed intraperitoneally. Cumulatively, five 
surgical interventions took place: one for hernia recurrence 
Fig. 2  Flowchart data analysis
Table 4  Recurrences and surgical site occurrences (SSOs) per subgroup from the algorithm
a 5 as one patient did not receive repair






Treatment algorithm Bilateral anterior CS (+BTA) Bilateral anterior CS
+BTA (+PPP)
Bilateral anterior CS 
+BTA
+PPP
Direct fascial closure achieved (%) 9 (100) 4 (80.0) 5 (62.5)
Recurrence (%) 0 (0) 1 (20.0) 2 (25.0)
Reoperation for either recurrence or complica-
tion (%)
0 (0) 2 (40.0) 3 (37.5)
Patients with ≥ 1 SSO 5 (55.5) 3 (60.0) 8 (100.0)
Total SSO 7 4 13
Surgical site infection (%) 4 (44.4) 3 (60.0) 6 (75.0)
 Superficial or wound dehiscence 4 (44.4) 1 (20.0) 2 (25.0)
 Deep 0 (0) 2 (40.0) 4 (50.0)
Seroma (%) 1 (11.1) 0 (0) 3 (37.5)
Hematoma (%) 2 (22.2) 0 (0) 2 (25.0)
Fascia dehiscence (%) 0 (0) 1 (20.0) 2 (25.0)
Enterocutaneous fistula formation (%) 0 (0) 0 (0) 0 (0)
Follow-up, months (median, range) 17 (10–40) 13 (12–31) 32.5 (19–60)
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and a deep SSI (4.5%) and four (18.2%) for other postopera-
tive complications.
Discussion
Preoperative preparation of patients with giant ventral and 
incisional hernias is essential to obtain the best possible out-
comes in terms of fascial closure rate. However, the effects 
of preoperative aids cannot be enhanced intraoperatively; the 
needed effect size has to be determined beforehand. There-
fore, a standardized preoperative strategy based on clinical 
and radiological parameters would be useful to estimate the 
needed effect size, informing on whether there is need for 
the use of BTA, PPP, or both. This cohort of 23 patients, 
treated according to a standardized algorithm for a giant 
ventral hernia with or without LOD, shows that BTA and 
PPP facilitate closure in ventral hernia repair. The primary 
fascial closure rate is 82%.
Component separation technique
Component separation techniques were used as the first tool 
in our algorithm to facilitate medialization of the rectus mus-
cles and closure of the anterior fascia. Surgeons that refrain 
from using component separation techniques might not 
achieve anterior fascial closure in all patients, as illustrated 
by Renard et al. (primary closure in 42 out of 45 patients, 
94%) [7]. In our study, anterior CST and TAR were applied 
in all but one patient; anterior CST was planned in addition 
to BTA for this patient, but BTA alone made anterior fascial 
closure possible. Despite being associated with more wound 
complications than TAR [22], anterior CST renders nearly 
6 cm of medialization of the rectus sheath (in postmortem 
human specimens), which can contribute to tension-free 
fascial closure [6]. In three patients in our study, to avoid 
intraperitoneal mesh placement and obtain anterior fascia 
closure, a unilateral TAR was done on one side to facilitate 
the closure of the posterior layer, and a unilateral anterior 
CST was done on the other side to ensure anterior fascial 
closure. In none of the patients both anterior CST and TAR 
were performed at the same side. Another component sepa-
ration method could be represented by the endoscopic exter-
nal oblique release as described by Rosen et al. [23], but as 
the achieved fascial advancement is limited to approximately 
80% of what can be achieved by an open technique, the latter 
was used in our study.
BTA
If anterior CST was estimated not to be enough for achieving 
anterior closure of the fascia, BTA was applied 4–6 weeks 
preoperatively. Only two protocols for BTA injections have 
so far been described: a three-point and five-point technique, 
respectively [20, 24]. Either one of these does not seem 
preferable over the other. BTA alone has been reported to 
give a 0.5–1.5 cm extra muscle length on each side of the 
abdominal wall on average. Other authors, however, found 
1–5 cm of myofascial advancement with the use of BTA 
[12, 13, 25–27]. In this study, the addition of BTA injections 
resulted in an extra increase in length of 2.0–3.0 cm of the 
lateral abdominal wall muscles, without causing additional 
complications. This finding is in line with the current litera-
ture; no complications of BTA use as a preoperative aid have 
been recorded, only minor inconveniences such as bruising 
after injection or a sensation of bloating [12]. One study 
even found an additional analgesic effect postoperatively of 
BTA [28].
PPP
In case a significant loss of domain of more than 20% was 
calculated preoperatively, the use of PPP was indicated, 
as shown in our algorithm (Fig. 1). PPP insufflations were 
performed daily with ambient air, until the patient expe-
rienced scapular pain, abdominal pain, or dyspnoea. The 
use of ambient air has been advocated, because nitrous 
oxide, carbon dioxide, and oxygen are absorbed four 
times faster in the peritoneal space than ambient air [10, 
29]. This causes the necessity to top up the volume often 
and with large quantities, while the use of ambient air 
results in easier maintenance of the pneumoperitoneum. 
No current consensus has been reached with regard to the 
amount of air to be injected, the frequency of the insuffla-
tions, and the length of the period the pneumoperitoneum 
should be maintained. Therefore, we used 2 L at the time 
of catheter placement intra-operatively and 1 L daily. It 
is suggested that PPP does not cause further benefit after 
6–10 days [29]. However, CT scans at 7 days after starting 
PPP showed only partial reduction of the hernia content in 
most of our patients, with limited air accumulation in the 
abdominal cavity itself. Therefore, we continued PPP for 
a maximum of 21 days. The average LOD was 53% before 
admission (median 29%). PPP caused a mean increase in 
HSV/ACV ratio of 4%. This increase is understandable 
from the law of Laplace, and was also found by Sabbagh 
et al. [8] reporting a 1%-increase in the ratio incisional 
hernia volume to total peritoneal content. Other authors, 
however, report a significant decrease in this ratio, from 
5 to 22% [7, 15, 30]. Their findings could justify the use 
of an abdominal binder between PPP sessions, to restrict 
air going to the hernia sac. However, air inside the hernia 
can cause lysis of possible adhesions and facilitate fascial 
closure [31]. Complications related to PPP in our study are 
predominantly hematomas, and one patient died because of 
an extensive bleeding and hemodynamic shock (however, 
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probably also related to his frail preoperative state). We 
treated all our patients with a therapeutic dosage of low 
molecular weight heparins from the start of PPP to prevent 
pulmonary embolisms. This serious complication has been 
described using laparoscopy [32] and is probably caused 
by increasing pressure at the level of the caval vein. How-
ever, in the light of our current findings—showing a high 
incidence of hematomas and bleeding complications—it 
might be better to use prophylactic dosage LMWH during 
PPP. Other authors describe subcutaneous emphysema, 
shoulder pain, abdominal pain, nausea, anxiety, intestinal 
perforation, and even mortality [7, 10, 15, 29, 31, 33]. 
Therefore, PPP asks for deliberate use in specific patient 
groups only. An evidence-based cut-off for LOD should be 
established to help surgeons decide on when to use PPP as 
a preoperative aid for hernia repair. As the primary goal is 
to close the anterior fascia, lenient cut-off for LOD should 
be utilized.
Complications
Surgical repair of these giant hernia defects was accom-
panied by several complications. Twelve patients (54.5%) 
experienced a surgical site infection (superficial or deep) 
and 3 patients (13.6%) had a recurrence. Five patients 
(22.7%) had to have a reoperation for either a recurrence 
or postoperative complication. These complications could 
not have entirely been avoided, as this is a very complex 
patient group. More than 90% of the patients were over-
weight (BMI > 25 kg/m2) and many had comorbidities (as 
shown in Table 1). When compared to the literature on 
ventral hernias with LOD, our SSI rate of 54.5% seems 
high. This might be partially be explained by the fact that 
we included wound dehiscence without proof of positive 
cultures in the superficial SSI rate. Other authors describe 
infection rates between 5 and 26% [7, 19, 34–38]. Also, 
the number of patients receiving a reoperation seems rela-
tively high with 22.7%, compared to a 10–15% reoperation 
rate [35, 38]. A possible explanation might be that we 
considered negative pressure wound therapy, as initiated 
with wound debridement in the OR, as a reoperation. Only 
one other study—more in line with our data—finds that 
one-third of the patients had to be reoperated [36]. These 
relatively high numbers could be due to the rather extreme 
width of the hernias researched in this study. Patient selec-
tion may have differed from the abovementioned studies. 
Additionally, the large number of comorbidities present 
in the researched group hinders the direct comparison of 
outcomes with findings from other authors. The number 
of patients having a recurrence (13.6%) is within line of 
expectations for these complicated hernias. Other authors 
report 4–16% recurrences [7, 19, 34–38].
Limitations
This is a retrospective cohort study, which is sensitive to 
bias. Also, only 23 patients were analyzed. The results must, 
therefore, be interpreted with caution, as these numbers 
are insufficient to provide sound statistical comparisons. 
Additionally, some patients had a relatively short follow-
up period, and CT scans were not always available to con-
firm that indication for PPP (as through our algorithm) was 
indeed present; these both are the drawbacks of the presented 
study. However, LOD is most of the time obvious at clinical 
examination, so bias on this point would be relatively low. 
Despite these limitations, the data of these patients add to 
the current body of knowledge about the combined use of 
BTA and PPP, what it can offer in hernia defect closure and 
the potential risks.
Implications
The combination of anterior CST and BTA seems safe and 
effective, leading to an anterior fascial closure rate of 82% in 
our study. PPP use might require more critical deliberation 
whether it is worth the risk as it resulted in a high compli-
cation rate of 29%. The standardized treatment algorithm 
prevented the surgeon from facing unforeseen intraoperative 
difficulties in closing the anterior fascia. However, the issue 
we came across during the usage of proposed algorithm 
in clinical practice is that it cannot always be successfully 
applied, as it is not a validated instrument. LOD was only 
measured when the estimated hernia width was > 18 cm, but 
had implications for the preoperative treatment, while LOD 
can also be present in hernias of less than 18 cm width. 
Meaning, undertreatment might have taken place: patients 
with LOD, but with an estimated effect width of < 18 cm, 
could possibly also have benefited from the additional PPP 
treatment.
On the other hand, overtreatment might also have been 
present, as the exact benefits and limitations of BTA treat-
ment remain unclear; in some patients, fascial closure might 
have been achieved without the use of BTA or PPP. Using 
BTA is expensive and, as BTA is not reimbursed by the 
insurance companies in Belgium, it poses an additional cost 
of approximately 500–600 euros for the patient.
PPP is described to cause a decrease in the LOD of the 
hernia, facilitating tension-free closure of the fascia during 
repair. An additional advantage of PPP is the lysis of adhe-
sions caused by the insufflated air [31]. A drawback of PPP 
is that it is even more expensive, as it required preoperative 
hospital stay in our study. As reported by Renard et al. [7], 
admission is not mandatory, but safety was considered of 
utmost importance in our study (as was observed with the 
patient suffering an AV-block during insufflation). Moreover, 
PPP showed a high complication rate of 29% which included 
397Hernia (2021) 25:389–398 
1 3
severe complications, PPP can cause pain, and PPP is gener-
ally experienced as unpleasant by patients, possibly resulting 
in a lower quality of life. An evidence-based protocol might 
be of help with indications for its use, and with regard to the 
amount of air to be insufflated and the number of days the 
pneumoperitoneum should be maintained. However, as it 
involves a very heterogeneous and relatively small group of 
patients with many variables influencing the final outcome, 
this might be elusive. The individual value of BTA, PPP, 
and CST cannot be determined based on the results from this 
study, nor has their value been elucidated in other studies, 
which only suggest optimistic results of the combined use of 
these methods [35]. The value of a specific preoperative aid 
is difficult to determine as the number of patients treated in 
the current study is too small and overtreatment might have 
taken place to be certain to achieve fascial closure. Because 
BTA is associated with fewer complications, it would be 
useful to distinguish between patients with a hernia with 
LOD that could be treated with BTA alone, CST alone, and 
patients that would need the combination of BTA and PPP, 
and possibly additional CST. This analysis clearly demon-
strates, however, that a standardized algorithm may be con-
sidered as a guidance during the pre- and intra-operative sur-
gical decision-making, but both preoperative CT assessment 
and clinical examination remain mandatory to determine the 
best approach for each individual patient. Larger studies and 
pooling of data would be required to give recommendations 
with regard to optimal selection of preoperative preparation 
methods.
Conclusions
This study is a description of 23 patients with complex ven-
tral hernia repair facilitated by Botulinum toxin A and pre-
operative progressive pneumoperitoneum. BTA seems safe 
to aid closure, whereas PPP requires critical consideration 
for its use. Further research should be conducted to deter-
mine both indications and outcome parameters for each of 
these preoperative tools in abdominal wall reconstruction.
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